SCRI Tissue Testing Registry

Terminated

• Conditions: Melanoma; Myelodysplastic Syndrome; Multiple Myeloma; Lymphoma
• Interventions: Other: Tissue Registry Study

• Registration Number: NCT00965861
• Lead Sponsor: SCRI Development Innovations, LLC

Brief Summary

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Detailed Description

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).

Study Timeline

• Study First Submitted: 2009-08-24
• Study First Submitted QC: 2009-08-25
• Study First Posted: 2009-08-26
• Study Start: 2010-05
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Status Verified: 2013-08
• Last Update Submitted: 2013-08-27
• Last Update Posted: 2013-08-28

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Patients must be >= 18 years of age.
• Patients must be able to provide written informed consent.

Exclusion Criteria

• Not Applicable

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Tissue Registry Study	The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.

Primary Outcome Measures

Name	Time	Method
To establish an electronic registry to store information from patients who have provided their consent allowing use of their tissue sample(s) for future testing.	120 months
To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases	120 months

Trial Locations

Locations (1)

Tennessee Oncology, PLLC; 🇺🇸 Nashville, Tennessee, United States